EPIX Valuation
ESSA Pharma Inc
$
1.670
- Overview
- Forecast
- Valuation
EPIX Relative Valuation
EPIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EPIX is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for EPIX's competitors is 3.27, providing a benchmark for relative valuation. ESSA Pharma Inc Corp (EPIX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
XOM
Exxon Mobil Corp
104.450
USD
-0.48%
AAPL
Apple Inc
202.700
USD
-2.01%
AMZN
Amazon.com Inc
201.340
USD
-1.34%
ORCL
Oracle Corp
158.050
USD
-1.41%
TSLA
Tesla Inc
337.211
USD
-1.92%
AVGO
Broadcom Inc
230.090
USD
-0.69%
META
Meta Platforms Inc
635.940
USD
-0.18%
WMT
Walmart Inc
96.300
USD
-1.53%
NVDA
NVIDIA Corp
133.069
USD
-0.98%
MSFT
Microsoft Corp
453.400
USD
-1.04%
FAQ
Is ESSA Pharma Inc (EPIX) currently overvalued or undervalued?
ESSA Pharma Inc (EPIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.83. The fair price of ESSA Pharma Inc (EPIX) is between to according to relative valuation methord.
What is ESSA Pharma Inc (EPIX) fair value?
How does EPIX's valuation metrics compare to the industry average?
What is the current P/B ratio for ESSA Pharma Inc (EPIX) as of May 21 2025?
What is the current FCF Yield for ESSA Pharma Inc (EPIX) as of May 21 2025?
What is the current Forward P/E ratio for ESSA Pharma Inc (EPIX) as of May 21 2025?